The DF/HCC Lung Cancer Program will continue to generate new discoveries in host susceptibility, exposure to pulmonary carcinogens, epidemiology, and pathogenesis of lung cancer, and will apply this information to develop novel prevention and therapeutic strategies to prevent lung cancer and improve the therapies of patients at risk or with lung cancer. The Lung Cancer Program was approved at the time of the last CCSG review in 2005 and was awarded a merit score of excellent to outstanding. The Lung Cancer Program has 60 members representing ten departments of HMS and'HSPH and six member institutions. Members have a broad range of expertise in epidemiology, molecular epidemiology, genetics, cancer biology, clinical trials and outcomes analyses. Program members have had neariy 692 publications in the last five years. Of these 692, 30% are intra-programmatic, 47% are inter-programmatic and 33% are inter-institutional peer-reviewed manuscripts. DF/HCC provides a mechanism for these Lung Cancer Program investigators to develop an interconnected program of population, basic and clinical scientists based on overiapping and interactive areas of expertise. The Lung Cancer Program has nearly $13 million in external support, including more than $6 million in NCI funding and $2.3 million in other peer-reviewed support.
The specific aims for the next five years are to: 1) Identify germline polymorphisms and determine their role in the susceptibility, pathogenesis and response to therapy and survival in lung cancer;2) Define pathogenic mechanisms underiying the development of lung cancer;and 3) Exploit the discoveries in pathogenesis to develop novel therapeutic approaches to thoracic malignancies.

Public Health Relevance

Lung cancer is the leading cause of cancer deaths in the United States. The delineation of the pathogenesis has helped identify driving mutations of lung cancer. The studies proposed in this application will continue to define host susceptibility, the steps involved in the development of cancer and the ability to inhibit these crucial steps to develop clinically effective targeted treatments for individual patients'tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601448
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$81,398
Indirect Cost
$60,778
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Lin, Ruei-Zeng; Lee, Chin Nien; Moreno-Luna, Rafael et al. (2017) Host non-inflammatory neutrophils mediate the engraftment of bioengineered vascular networks. Nat Biomed Eng 1:
Wang, Meng; Han, Jing; Marcar, Lynnette et al. (2017) Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. Cancer Res 77:2018-2028
Ignatius, Myron S; Hayes, Madeline N; Lobbardi, Riadh et al. (2017) The NOTCH1/SNAIL1/MEF2C Pathway Regulates Growth and Self-Renewal in Embryonal Rhabdomyosarcoma. Cell Rep 19:2304-2318
Nugent, Alicia A; Park, Jong G; Wei, Yan et al. (2017) Mutant ?2-chimaerin signals via bidirectional ephrin pathways in Duane retraction syndrome. J Clin Invest 127:1664-1682
Breitkopf, Susanne B; Taveira, Mateus De Oliveira; Yuan, Min et al. (2017) Serial-omics of P53-/-, Brca1-/- Mouse Breast Tumor and Normal Mammary Gland. Sci Rep 7:14503
Bowden, John A; Heckert, Alan; Ulmer, Candice Z et al. (2017) Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human Plasma. J Lipid Res 58:2275-2288
Lindsley, R Coleman; Saber, Wael; Mar, Brenton G et al. (2017) Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. N Engl J Med 376:536-547
Mita, Monica M; Mita, Alain C; Moseley, Jennifer L et al. (2017) Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies. Br J Cancer 117:1258-1268
Hu, Yuebi; Alden, Ryan S; Odegaard, Justin I et al. (2017) Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin Cancer Res 23:7351-7359
Lam, Hilaire C; Liu, Heng-Jia; Baglini, Christian V et al. (2017) Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget 8:64714-64727

Showing the most recent 10 out of 371 publications